Understanding why some cancer patients fail to respond to immunotherapy is one of oncology's most pressing puzzles. A newly identified mechanism involving a mirror-image amino acid — d-serine — may help explain how gastrointestinal tumors quietly disarm the immune system, and why measuring a simple blood metabolite could predict who benefits from checkpoint inhibitors.
D-serine (D-ser) is the D-enantiomer of the common amino acid serine, meaning it is a molecular mirror image of its proteinogenic counterpart. While D-amino acids have been detected in mammalian biology for decades, their functional roles in cancer immunity have remained largely uncharacterized. This multi-cohort study, published in EBioMedicine, combined murine MC38 tumor models, orthotopic gastric cancer organoid allografts, single-cell RNA sequencing of tumor-infiltrating immune cells, and clinical plasma sampling across three human cohorts (total gastric cancer patients exceeding 150 individuals). D-ser supplementation accelerated tumor progression in animal models by simultaneously suppressing CD8+ cytotoxic T cell activity and amplifying SPP1-associated immunosuppressive macrophage signaling — a dual immune sabotage. Clinically, plasma, urine, and stool concentrations of D-ser were meaningfully elevated in gastric cancer patients relative to 87 healthy controls, and higher plasma D-ser correlated with advanced disease stage, reduced immune infiltration, and worse outcomes following anti-PD-1 antibody therapy.
This work situates D-ser within the expanding concept of metabolic immune checkpoints — endogenous small molecules that modulate immune tone independently of classical PD-1/PD-L1 or CTLA-4 pathways. The SPP1 macrophage axis identified here has been implicated in immunosuppressive tumor microenvironments across multiple cancer types, lending mechanistic plausibility. That said, critical limitations temper immediate clinical translation: the human cohorts are small and observational, causality from D-ser to immune suppression in humans remains unproven, and gastric cancer biology may not generalize broadly. Nonetheless, the finding that a circulating, measurable metabolite tracks with immunotherapy responsiveness is analytically significant. If validated in larger prospective trials, plasma D-ser could emerge as an accessible biomarker stratifying patients before checkpoint inhibitor treatment — an incremental but genuinely promising step toward precision immuno-oncology.